CONTENTS 目 錄 | 公司資料 Corporate Information | | 2 | | --- | --- | --- | | Management Discussion and Analysis | 管理層討論與分析 | 4 | | Corporate Governance Report 企業管治報告 | | 16 | | 董事履歷 Directors' Biographies | | 32 | | Directors' Report 董事會報告 | | 38 | | Independent Auditor's Report 獨立核數師報告 | | 59 | | Consolidated Statement of Profit or Loss 綜合損益表 | | 67 | | Consolidated Statement of Profit or Loss and | 綜合損益及其他全面 | | | 收益表 Other Comprehensive Income | | 69 | | Consolidated Statement of Financial Position 綜合財務狀況表 | ...

BA Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|------------|-------|-------| | | | | | | | | | | | (Incorporated in the Cayman Islands with limited liability) (於同曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 | Love China | | | | | | | | | Hong KongHong Kong | Yourself | | | | INTERIM REPORT | | | | ２０２４ 中期報告 | --- | --- | |------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 截至二零二四年六月三十日止六個月期間 中期業績公告 三愛健康產業集團有限公司（「三愛健康產業」或「本公司」）董事（「董事」）會（「董事 會」）謹此提呈本公司及其附屬公司（統稱「本集團」）截至二零二四年六月三十日止六 個月期間（「本期間」）的未經審核簡明綜合財務報表，連同二零二三年同期的比較數 字。 – 1 – 簡明綜合損益表 截至二零二四年六月三十日止六個月 | --- | --- | --- | --- | |------------------------------------|-------|----------------------------------------------------|---------------- ...

CONTENTS 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Management Discussion and Analysis | 管理層討論及分析 | 4 | | Corporate Governance Report | 企業管治報告 | 14 | | Directors' Biographies | 董事履歷 | 28 | | Directors' Report | 董事會報告 | 32 | | Independent Auditor's Report | 獨立核數師報告 | 50 | | Consolidated Statement of Profit or Loss | 綜合損益表 | 57 | | Consolidated Statement of Profit or Loss and | 綜合損益及其他全面 | 58 | | Other Comprehensive Income | 收益表 | | | Consolidated Statement of Financial Position | 綜合財務狀況表 | ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告 財 務 摘 要 – 2 – 綜 合 損 益 表 | | | | | | | | | | | | | | | | | 二 | 零 | 二 | 三 年 | 二 | 零 | 二 | 二 年 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Corporate Information 公司資料 BOARD OF DIRECTORS Executive Directors Mr. Chen Chengqing Professor Zhang Rongqing Mr. Gao Borui Mr. Yuan Chaoyang Mr. She Hao Non-executive Director Mr. Xiu Yuan Independent Non-executive Directors Professor Zhu Yi Zhun Mr. Khor Khie Liem Alex Mr. Zhang Ruigen COMPANY SECRETARY Ms. Li Yuen Shan AUTHORIZED REPRESENTATIVES Mr. She Hao Ms. Li Yuen Shan AUDIT COMMITTEE Mr. Khor Khie Liem Alex (Chairman) Professor Zhu Yi Zhun Mr. Zhang Ruigen REMUNERATION COMMITTEE Mr. Khor Khie Liem ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公告全部或任何部份內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 期 間 中 期 業 績 公 告 三愛健康產業集團有限公司（「三愛健康產業」或「本公司」）董事（「董事」）會 （「董 事 會」）謹 此 提 呈 本 公 司 及 其 附 屬 公 司（統 稱「本 集 團」）截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 期 間（「本 期 間」）的 未 經 審 核 簡 明 綜 合 財 務 報 表， 連同二零二二年同期的比較數字。 ...

Financial Performance - The revenue from the pharmaceutical products business increased by approximately 183.6% to approximately RMB152.65 million in 2022, compared to RMB53.82 million in 2021[17]. - Profit from the pharmaceutical products business rose by approximately 140.6% to RMB70.90 million for the Reporting Period, up from approximately RMB29.47 million in 2021[17]. - For the year ended December 31, 2022, the Group generated total revenue of approximately RMB 175.92 million, representing an increase of approximately 160.2% compared to RMB 67.61 million for the year ended December 31, 2021[47][51]. - Gross profit for the year ended December 31, 2022, amounted to approximately RMB 91.68 million, with a gross profit margin of 52.1%, down from 60.0% in 2021[54][61]. - Profit attributable to owners of the Company was approximately RMB 29.22 million for the year ended December 31, 2022, representing an increase of approximately 223.6% compared to RMB 9.03 million in 2021[56][63]. Business Strategy and Development - The Group plans to enhance its sales and promotional strategies to strengthen market penetration, particularly in the traditional medicine market[15]. - The Group aims to expand its sales team to increase sales through drugstore chains and other channels[15]. - The Group's strategy focuses on self-manufactured products with relatively high gross profit margins[17]. - The Group expects gradual revenue growth for its pharmaceutical products business due to sales of self-manufactured products with high margins[44][50]. - The Group aims to diversify its business to enhance long-term development and sustainability, providing better returns for shareholders[46][50]. Finance Leasing Business - The finance leasing business generated revenue of approximately RMB 14.82 million (2021: RMB 9.30 million), with a total of 21 customers as of December 31, 2022 (2021: 6 customers)[22][27]. - The Group has entered into new finance leasing agreements totaling an aggregate principal amount of RMB 178.1 million with interest rates ranging from 6.0% to 7.0% per annum during the reporting period[33]. - The weighted average term of finance leases entered into is 1.4 years (2021: 1.7 years), with all leases requiring repayment by installments[34]. - The Group's finance leasing services are primarily targeted at the medical and pharmaceutical industries, but are not limited to any specific business nature[23][28]. - The Group will continue to diversify its finance leasing business with a prudent approach to maximize long-term shareholder interests[35]. Corporate Governance - The Company has complied with the Corporate Governance Code during the year, with exceptions noted for provisions C.2.1 and C.1.6[98]. - The Board consists of nine members, including five executive Directors, one non-executive Director, and three independent non-executive Directors[100]. - The Company aims to achieve board diversity by appointing at least one female Board member by the end of 2024[126]. - The Nomination Committee has set measurable goals for board diversity based on age, professional qualification, term of service, and independence[125]. - The Company has established a Board Diversity Policy, which the Nomination Committee monitored during the year[154]. Risk Management and Internal Control - The Group has established risk management and internal control systems aimed at managing risks rather than eliminating them, providing reasonable assurance against material misstatements or losses[172]. - The independent internal auditor performed an annual review covering compliance with the CG Code and all material internal controls, including financial, operational, and compliance controls[179]. - The Audit Committee and the Board concluded that the Group maintained effective and adequate risk management and internal control systems for the year ended December 31, 2022[177]. - An independent professional firm was engaged as an outsourced internal auditor to assist in evaluating the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2022[173]. - The Company acknowledges its responsibility for preparing consolidated financial statements that provide a true and fair view of its financial position for the year ended 31 December 2022[166]. Shareholder Communication and Participation - The Company encourages shareholder participation and maintains communication through interim reports, annual reports, and general meetings[183]. - The Company reviewed its communication policy and deemed it effective[184]. - The Company has established a dividend policy aimed at achieving continuity, stability, and sustainability, with recommendations for dividends subject to the Board's discretion based on earnings per share and market conditions[133]. - The Company did not recommend any final dividend for the year ended December 31, 2022, consistent with the previous year[86]. - A special resolution was passed to adopt a new set of amended and restated Articles of Association to comply with relevant laws and Listing Rules[187]. Leadership and Management - The executive director Mr. Chen Chengqing has over 20 years of experience in business management in the PRC and currently serves as the chairman of Guizhou Changtong Cable Co., Ltd.[193]. - Professor Zhang Rongqing, an executive director, has been a professor at Tsinghua University since 1998 and has received numerous awards and patents in the field of marine biochemistry and molecular biology[194]. - Mr. Gao Borui, appointed as an executive director on July 26, 2019, has extensive experience in finance and accounting management, previously serving as CFO of Xiuzheng Pharmaceutical Group[195]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic management and leadership[193][194][195]. - The company’s leadership team comprises individuals with diverse backgrounds and extensive experience in their respective fields, contributing to its strategic direction[193][194][195].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就 因本公告全部或任何部份內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告 財務摘要 — 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度，收 益 增 加 約160.20%至 約 人民幣175.92百萬元（二零二一年：約人民幣67.61百萬元）。 — 截至二零二二年十二月三十一日止年度，毛利約為人民幣91.68百萬 元（二零二一年：約人民幣40.56百萬元）。 — 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度，毛 利 率 約 為52.11%（二 零 二一年：約59.99%）。 ...

BA Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 (Incorporated in the Cayman Islands with Ilmited Ilability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 �中國 Love China 壓香港 Love Hone Interim Report 中期報告 Corporate Information 公司资料 | --- | --- | |--------------------------------------------------------------------------------------------------|--------------------------------------------------| | | | | BOARD OF DIRECTORS Executive Directors Mr. Chen Chengqing Professor Zhang Rongqing Mr. Gao Borui | 董事會 ...